NCT03240016已完成2 期
ABLE: Phase II, Single Arm, Two-stage Study of Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Percentage of Patients That Respond to Treatment
研究概览
简要总结
This is a phase 2, single arm, two-stage study of abraxane with an anti-PD1/PDL1 (pembrolizumab) in cisplatin-ineligible patients with advanced urothelial cancer.
Each cycle last 21-days. All subjects will receive pembrolizumab via IV on day 1, and abraxane via IV on Day 1 and Day 8 of each cycle. Subjects may continue to receive the study regimen until they experience disease progression or unacceptable toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with recurrent unresectable locally advanced or metastatic urothelial carcinoma (aka transitional cell carcinoma).
- •Patients may be either cisplatin-ineligible or platinum-refractory.
- •Histological or cytologically proven urothelial carcinoma.
- •Have measurable disease based on RECIST 1.1
- •Has urothelial cancer that is not suitable for local therapy administered with curative intent if not already administered.
- •Must have recovered (i.e., AE <= Grade 1 or stable) from AEs due to a previously administered agent.
- •ECOG Performance Status of 0, 1 or
- •(Eastern Cooperative Oncology Group Performance Status: an attempt to quantify cancer patients' general well-being and activities of daily life. The score ranges from 0 to 5 where 0 is asymptomatic and 5 is death.)
- •Prior neoadjuvant or adjuvant systemic therapy or local intravesical chemotherapy or immunotherapy is permitted.
- •Adequate organ and marrow function
- •Women of child-bearing potential must either commit to true abstinence or agree to use, and be able to comply with, effective contraception without interruption, 28 days prior to starting IP therapy, and while on study medication or for a longer period if required by local regulations following the last dose of IP; and have a negative serum pregnancy test result at screening
- •Male subjects must practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for 6 months following drug discontinuation, even if he has undergone a successful vasectomy.
- •Patients must have < Grade 2 pre-existing peripheral neuropathy
- •Be ≥18 years of age as of date of signing informed consent
- •Voluntarily agree to participate by providing written informed consent/assent for the trial
排除标准
- •Prior exposure to immune-mediated therapy
- •History of allogenic organ transplantation that requires ongoing use of immunosuppressive agents is NOT permitted
- •Active or prior documented autoimmune or inflammatory disorders are NOT permitted
- •Current or prior use of immunosuppressive medication(s) within 14 days before study treatment is NOT permitted.
- •Brain metastases or spinal cord compression are NOT permitted unless they have been treated with the patient's condition being stable clinically and radiologically for 28 calendar days and off steroids for at least 14 days prior to the start of study treatment.
- •Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) is NOT permitted.
- •Receipt of live attenuated vaccine within 30 days prior to the first study treatment is NOT permitted.
- •Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigation device within 28 calendar days of the first dose of treatment.
- •CTCAE Grade > 1 peripheral neuropathy is NOT permitted
- •If subjects received major surgery they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting trial therapy
- •Has a known additional malignancy that is progressing or requires active treatment
- •Has a history of severe hypersensitivity reaction to nab-paclitaxel or anti-PD1/PDL1
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- •Pregnancies:
- •Females: nab-paclitaxel can cause harm to an unborn child if given to a pregnant woman. Females may not take part in this study if pregnant or breast-feeding for 6 months after last dose of study drug.
- •Males: Male subjects should avoid fathering a child while receiving study medication and for 6 months after the last dose of study medication. Males must agree to complete abstinence from heterosexual contact or use a condom during sexual contact with a female of child bearing potential while receiving study medication and within 6 months after last dose of study medication.
- •Subjects (both males and female) should practice effective contraception during study and for 6 months after the last dose of study medication (Section 3.1.8 i, ii).
- •Patients with biliary obstruction or biliary stent are excluded.
研究组 & 干预措施
Pembrolizumab and Abraxane
Experimental
Pembrolizumab 200mg IV D1 Abraxane 100mg/m^2 IV D1 and D8 21 Day Cycles
干预措施: Abraxane (Drug)
Pembrolizumab and Abraxane
Experimental
Pembrolizumab 200mg IV D1 Abraxane 100mg/m^2 IV D1 and D8 21 Day Cycles
干预措施: Pembrolizumab (Drug)
结局指标
主要结局
Percentage of Patients That Respond to Treatment
时间窗: 24 months post treatment, an average of 7.5 months
The Overall Response Rate (ORR) will be the percentage of patients that achieve either complete response (CR) or partial response (PR). CR is defined as the disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. There can be no appearance of new lesions.
次要结局
- Duration of Response(24 months post treatment)
- Progression Free Survival Time(24 months post treatment)
- Median Number of Patients Alive at 12 and 24 Months(12 and 24 months post treatment)
- Median Duration of Therapy(from the start of therapy, up to 24 months)
- Percentage of Patients That Completely Respond to Treatment(24 months post treatment, an average of 7.5 months)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian CancerLow Grade Serous CarcinomaFallopian Tube CancerOvarian CancerPrimary Peritoneal CarcinomaNCT04575961North Eastern German Society of Gynaecological Oncology33
招募中
2 期
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHLRelapsed Hodgkin LymphomaRefractory Hodgkin LymphomaRelapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaB-cell LymphomaNCT06484920Rita Assi24
已完成
2 期
Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial CancerEndometrial NeoplasmsNCT03276013Vall d'Hebron Institute of Oncology48
进行中（未招募）
2 期
Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO TrialNeoadjuvantImmunotherapySarcoma,Soft TissueRadiation TherapyNCT06128863Maria Sklodowska-Curie National Research Institute of Oncology40
已完成
2 期
Pembro/Carbo/Taxol in Endometrial CancerEndometrial CancerEndometrial AdenocarcinomaNCT02549209Daniela Matei, MD46